| Cav3.1 (T-type Calcium Channel Alpha-1G) | |
|---|---|
| Protein Name | T-type Calcium Channel Alpha-1G |
| Gene | CACNA1G |
| UniProt ID | O43497 |
| Ion Channel Family | Voltage-gated calcium channel (Cav3) |
| Molecular Weight | 262 kDa |
| Subcellular Localization | Cell membrane (neuronal dendrites and soma) |
| Protein Structure | 24 transmembrane segments, 4 domains |
| Channel Type | Low-voltage-activated (LVA) |
CACNA1G encodes the alpha-1G subunit of low-voltage-activated (LVA) T-type calcium channels, commonly known as Cav3.1. T-type calcium channels are unique among voltage-gated calcium channels in their ability to activate at relatively negative membrane potentials, making them crucial for neuronal pacemaking, burst firing, and thalamic oscillations[1]. Cav3.1 is the principal T-type channel isoform in the thalamus and is widely expressed throughout the central nervous system, where it plays essential roles in sleep-wake cycles, sensory processing, and neuronal excitability regulation.
Dysregulation of Cav3.1 channel function has been implicated in multiple neurological disorders, including epilepsy, migraine, and neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD)[2]. The channel's unique gating properties—rapid activation and inactivation, and the ability to generate rebound low-threshold calcium spikes—make it a critical player in both normal neuronal function and pathological states.
Cav3.1 is a member of the voltage-gated calcium channel superfamily and shares the general architecture of these proteins[3]:
Alpha-1 Subunit Structure:
Unique Features of Cav3.1:
Cav3.1 exhibits distinctive gating characteristics[4]:
The energetics of Cav3.1 gating involve[5]:
Cav3.1 channels play a critical role in spontaneous neuronal firing, particularly in thalamic neurons and certain cortical interneurons[6]:
In the thalamus, Cav3.1 is essential for[7]:
Cav3.1 channels contribute to sensory processing in various ways:
Cav3.1 channels on dendritic shafts enable:
Cav3.1 channel dysfunction contributes to several aspects of Alzheimer's disease pathology[8]:
Calcium Dysregulation: AD is characterized by abnormal calcium signaling. T-type channels contribute to this through:
Neuronal Hyperexcitability: AD neurons often show hyperexcitability, partly due to:
Therapeutic Implications: Modulating Cav3.1 activity may provide benefits:
In Parkinson's disease, Cav3.1 plays a complex role in basal ganglia function[9]:
Thalamic Dysfunction: PD affects thalamic oscillations through:
Deep Brain Stimulation: T-type channels are implicated in the mechanisms of DBS:
Dopaminergic Modulation: Dopamine modulates T-type channel function:
Cav3.1 mutations cause or contribute to several epilepsy syndromes[10]:
Childhood Absence Epilepsy: Gain-of-function mutations in CACNA1G:
Febrile Seizures: Temperature-sensitive mutations
Therapeutic Targeting: T-type channel blockers are used clinically:
Cav3.1 contributes to migraine pathophysiology:
Cav3.1 activity is modulated by multiple intracellular signaling pathways[11]:
Protein Kinase C (PKC):
Calmodulin:
cAMP/PKA:
Cav3.1 interacts with various ion channels:
T-type calcium channels are therapeutic targets for[12]:
Anticonvulsants:
Migraine Prevention:
Movement Disorders:
Several approaches are being explored[13]:
Selective T-type Blockers:
Channel Subtype Specificity:
State-Dependent Modulation:
Cav3.1 is expressed throughout the brain[@Zhang2013]:
CACNA1G mutations are associated with several neurological conditions[14]:
Gain-of-Function Mutations:
Loss-of-Functional Mutations:
Perez-Reyes E. Molecular physiology of low-voltage-activated T-type calcium channels. Physiol Rev. 2003. ↩︎
Sheng W, et al. T-type calcium channels in neurodegenerative diseases. Cell Mol Neurobiol. 2022. ↩︎
Catterall WA. Structure and regulation of voltage-gated Ca2+ channels. Annu Rev Cell Dev Biol. 2000. ↩︎
Talavera K, Nilius B. Biophysical properties of T-type Ca2+ channels. Cell Calcium. 2003. ↩︎
Gomora JC, et al. Energetics of activation and modulation of T-type calcium channels. J Gen Physiol. 2001. ↩︎
Dreyfus FM, et al. T-type calcium channels in thalamocortical oscillations. J Neurosci. 2010. ↩︎
Huguenard JR. Neuronal circuitry and the targeting of calcium channels. Annu Rev Physiol. 1998. ↩︎
Cain SM, et al. T-type calcium channel gating and neuronal excitability. Channels. 2018. ↩︎
Lu B, et al. T-type calcium channels in synaptic plasticity and disease. Neuropharmacology. 2015. ↩︎
Ernst WL, et al. T-type channelopathies in epilepsy and migraine. Nat Rev Neurol. 2019. ↩︎
Chemin J, et al. Properties and modulation of T-type calcium channels in neuronal cells. Neuroscience. 2002. ↩︎
Zamponi GW, et al. Targeting voltage-gated calcium channels for neurological disease therapy. Nat Rev Drug Discov. 2020. ↩︎
Cheong E, et al. Cav3.1 dysfunction and therapeutic targeting in neurological disease. Pharmacol Res. 2023. ↩︎
Huang H, et al. Cav3.1 channel dysfunction in neurological disorders. Brain Res. 2017. ↩︎